MAB1620
Anti-Cytokeratin 5 Antibody, 6, clone D5/16B4
clone D5/16B4, Chemicon®, from mouse
Synonym(s):
58 kDa cytokeratin, Cytokeratin-5, CK-5, Keratin-5, K5, Type-II keratin Kb5
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
clone
D5/16B4, monoclonal
species reactivity
rat, mouse, human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... KRT5(3852)
General description
The cytokeratins are a family of intermediate filaments found in almost all epithelial cells. They are divided into four subclasses depending on their patterns of reactivity and electrophoretic characteristics and are also arranged I a numbered series of 20 or more acoring to molecular weight and isoelectric point (Quinlan et al. 1985). Types 5 and 6 of cytokeratin (CK5/6) are in high frequency in mesothelial cells, as opposed to cells of adenocarcinoma. CK5/6 has been shown to be a reliable marker for mesothelioma and squamous cell carcinoma of the lung and Bowen′s disease. It does not react with pulmonary adenocarcinoma.
Specificity
Expected to cross-react with mouse and rat.
Reacts with human cytokeratin 5 on immunoblots of cytoskeletal preparations of epidermis and non-cytokeratinizing epithelium (Abstract: European Symposium of the Biology of the Cytoskeleton, Helsinki, 18-21, 6, 89, 1989) and on tissue sections. Shows reactivity with cytokeratin 6 and weak reactivity with cytokeratin 4 on immunoblots. No cross-reactivity with cytokeratins 1, 7, 8, 10, 13, 14, 18 or 19. MAB1620 recognizes basal cells and a part of the stratum spinosum in the normal pavement epithelium. The antibody may be useful for distinction of low differentiated pavement epithelium carcinoma and adenocarcinoma. The antibody works on formalin fixed tissues.
Immunogen
Purified cytokeratin 5 (Exp. Cell Res. (1986) 162:114; J. Invest. Dermatology (1987) 88:191).
Application
Anti-Cytokeratin 5 Antibody, 6, clone D5/16B4 is an antibody against Cytokeratin 5 for use in IF, IH(P) & WB.
Immunohistochemistry (frozen or paraffin sections):
A 1:50-1:100 dilution from a previous lot was used for paraffin, high-temperature antigen retrieval required (Pressure cooker, Citrate/EDTA buffer pH 6.0, 4 minutes at full pressure).
Immunofluorescence:
A previous lot of this antibody was used in Immunofluorescence.
Western blot:
Recognizes a 58kDa and 56kDa band corresponding to cytokeratin 5 and 6.
Optimal working dilutions must be determined by end user.
A 1:50-1:100 dilution from a previous lot was used for paraffin, high-temperature antigen retrieval required (Pressure cooker, Citrate/EDTA buffer pH 6.0, 4 minutes at full pressure).
Immunofluorescence:
A previous lot of this antibody was used in Immunofluorescence.
Western blot:
Recognizes a 58kDa and 56kDa band corresponding to cytokeratin 5 and 6.
Optimal working dilutions must be determined by end user.
Research Category
Cell Structure
Cell Structure
Research Sub Category
Cytoskeleton
Cytoskeleton
Quality
Routinely evaluated by Western Blot on A431 lysates.
Western Blot Analysis:
1:500 dilution of this lot detected cytokeratin 5/6 on 10 ug of A431 lysates.
Western Blot Analysis:
1:500 dilution of this lot detected cytokeratin 5/6 on 10 ug of A431 lysates.
Target description
Cytokeratin 4 (59 kDa), Cytokeratin 5 (58 kDa) and Cytokeratin 6 (56 kDa).
Physical form
Format: Purified
Protein A purified
Purified mouse monoclonal IgG1 in buffer containing 0.02 M Phosphate buffer, 0.25 M NaCl, pH 7.6 with 0.1% sodium azide.
Storage and Stability
Stable for 6 months at 2-8°C in undiluted aliquots from date of receipt.
Analysis Note
Control
A431 cell lysate, human bladder tumor tissue.
A431 cell lysate, human bladder tumor tissue.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
recommended
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
D Allende et al.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 26(3), 314-318 (2012-09-27)
Patients with Barrett's esophagus are at risk for dysplasia and esophageal adenocarcinoma. Although surgery was the mainstay treatment for Barrett's dysplasia and cancer, patients with high-grade dysplasia and early cancers now have several nonsurgical treatment options. Most of the endoscopic
Julien Parra et al.
Scientific reports, 7, 43682-43682 (2017-03-09)
Post-translational modifications (PTMs) are essential processes conditioning the biophysical properties and biological activities of the vast majority of mature proteins. However, occurrence of several distinct PTMs on a same protein dramatically increases its molecular diversity. The comprehensive understanding of the
Variation and frequency of cytokeratin polypeptide patterns in human squamous non-keratinizing epithelium.
Wild, G A and Mischke, D
Experimental Cell Research, 162, 114-126 (1986)
Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients.
Winczura, P; Sosinska-Mielcarek, K; Duchnowska, R; Badzio, A; Lakomy, J; Majewska et al.
Pathology Oncology Research null
Katarzyna Sosińska-Mielcarek et al.
Breast (Edinburgh, Scotland), 22(6), 1178-1183 (2013-09-26)
There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service